消化器がん患者における2時間対6時間のオキサリプラチン注入
胃腸がん患者の神経障害および薬物動態に対する 2 時間対 6 時間のオキサリプラチン注入の効果の第 II 相評価
This phase II trial studies how well giving oxaliplatin over 6 hours works in treating nerve damage in patients with gastrointestinal cancers. Oxaliplatin can cause side effects such as nerve damage that may delay or reduce the dose of oxaliplatin. Giving oxaliplatin over a longer period of time (6 hours) may prevent or delay the development of nerve damage, which may keep patients on standard doses of chemotherapy longer, without having to delay treatment.
調査の概要
詳細な説明
PRIMARY OBJECTIVE:
I. To determine the effect of 2 versus 6-hour oxaliplatin infusion time on the difference in severity of sensory neuropathy as measured by patient reported outcome (PRO) scores on the European Organization for Research and Treatment of Cancer (EORTC) chemotherapy-induced peripheral neuropathy (CIPN-20) scale at the initiation of cycle 4.
SECONDARY OBJECTIVES:
I. Pharmacokinetic parameters of maximum concentration (Cmax), area under the curve (AUC), time of maximum concentration (tmax), clearance, and half life (t1/2) of platinum ultra-filtrate.
II. CIPN-20 sensory score changes over the duration of therapy as measured by a cumulative area-under-the curve score.
III. Clinical outcomes including duration of therapy, oxaliplatin dose reductions, delays in therapy, and overall dose intensity and delivery of oxaliplatin.
IV. Relationship between oxaliplatin Cmax, patient-reported acute neurotoxicity, and chronic neurotoxicity by CIPN-20 scores.
OUTLINE: Patients are randomized to 1 of 2 groups.
2-hour infusion group: Patients receive oxaliplatin intravenously (IV) and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
6-hour infusion group: Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1, 3, 6, 12, and 18 months.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Amber Draper, PharmD
- メール:amber.draper@emoryhealthcare.org
研究連絡先のバックアップ
- 名前:Olumide B. Gbolahan, MBBS, MSc
- 電話番号:404-778-0032
- メール:ogbolah@emory.edu
研究場所
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Emory University Hospital/Winship Cancer Institute
-
コンタクト:
- Allyson Anderson
- 電話番号:404-686-0239
- メール:allyson.anderson@emory.edu
-
主任研究者:
- Olumide B. Gbolahan, MBBS, MSc
-
Atlanta、Georgia、アメリカ、30308
- 募集
- Emory University Hospital Midtown
-
コンタクト:
- Allyson Anderson
- 電話番号:404-686-0239
- メール:allyson.anderson@emory.edu
-
主任研究者:
- Olumide B. Gbolahan, MBBS, MSc
-
Atlanta、Georgia、アメリカ、30342
- 募集
- Emory Saint Joseph's Hospital
-
主任研究者:
- Olumide B. Gbolahan, MBBS, MSc
-
コンタクト:
- Kathleen M. Coleman
- 電話番号:404-251-1278
- メール:kathleen.marie.coleman@emory.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Confirmed diagnosis of a gastrointestinal cancer
- Plan for 4 or more cycles of FOLFOX6 (fluorouracil [with leucovorin] and oxaliplatin) containing chemotherapy
- Histologically confirmed, measurable or evaluable disease. Patients with advanced or metastatic disease should have at least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Patients in the adjuvant treatment setting planned to have > 4 cycles of FOLFOX-containing chemotherapy are eligible and will be followed per standard of care
- Absolute neutrophil count (ANC) ≥ 1,500/µL (no white blood cell growth factors allowed to meet requirement)
- Platelets ≥ 75,000/µL (may be transfused up to 72 hours prior to day 1 to meet requirement)
- Hemoglobin ≥ 8 g/dL (may be transfused up to 72 hours prior to day 1 to meet requirement)
- Creatinine clearance > 30 mL/min by Cockcroft-Gault, to preserve similar dosing (85 mg/m²) for analysis
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- Signed informed consent
- Adequate birth control when appropriate
Exclusion Criteria:
-
Any preexisting grade 2 or higher peripheral neuropathy
-
Patients currently receiving anticancer therapies or who have received any focal or systemic anticancer therapy within 14days of the start of FOLFOX6
-
Known intolerance or hypersensitivity to any agent in FOLFOX6 or concurrent agents
-
Patients who have any known severe and/or uncontrolled medical conditions such as:
- Unstable angina pectoris, symptomatic heart failure; (New York Heart Association class III or IV), myocardial infarction ≤ 6 months prior, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease
- Active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, or decompensated liver disease
-
Patients with any history of severe hemorrhage requiring ≥ 4 units of packed red blood cells (RBCs) in a 48-hour period
-
Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study
-
Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 14days prior to dosing
-
Pregnant or nursing (lactating) women
-
Women of childbearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must use highly effective methods of contraception during the study and 8 weeks after. Highly effective contraception methods include combination of any two of the following:
- Use of oral, injected or implanted hormonal methods of contraception or;
- Placement of an intrauterine device (IUD) or intrauterine system (IUS);
- Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository;
- Total abstinence or;
- Male/female sterilization Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:2-hour infusion group
Patients receive oxaliplatin IV and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. |
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
|
|
実験的:6-hour infusion group
Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. |
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Effect of 2 versus 6-hour oxaliplatin infusion time on neuropathy as measured by patient reported outcome (PRO) scores on the European Organization for Research and Treatment of Cancer (EORTC) chemotherapy-induced peripheral neuropathy (CIPN-20) scale
時間枠:Baseline up to 60 days (course 4)
|
The EORTC-CIPN-20 sub-scales will be computed according to the standard scoring algorithm and then transformed to a 0 to 100 scale, where high scores mean less symptom burden. The primary outcome measure of difference in sensory scores of the two groups between baseline and the initiation of cycle 4 will be the driver of the analysis. |
Baseline up to 60 days (course 4)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximum concentrations achieved (Cmax)
時間枠:At baseline and at 1, 2, 4, 6, 48, and 192 hours after initiation of oxaliplatin
|
The study will focus on maximum concentrations achieved (Cmax) with each infusion time. Data will be analyzed using non-compartmental methods via Phoenix WinNonlin analytical software, version 8.0 or higher. |
At baseline and at 1, 2, 4, 6, 48, and 192 hours after initiation of oxaliplatin
|
|
Changes in tumor size
時間枠:Up to 18 months after completion or discontinuation of chemotherapy
|
The study will assess changes in tumor size per standard of care assessments at screening and every 2 months. |
Up to 18 months after completion or discontinuation of chemotherapy
|
|
Duration of therapy
時間枠:Up to 18 months after completion or discontinuation of chemotherapy
|
Duration of therapy will be recorded. |
Up to 18 months after completion or discontinuation of chemotherapy
|
|
Dose density
時間枠:Up to 18 months after completion or discontinuation of chemotherapy
|
Dose density will be recorded. |
Up to 18 months after completion or discontinuation of chemotherapy
|
|
Frequency of dose holds or reductions
時間枠:Up to 18 months after completion or discontinuation of chemotherapy
|
Frequency of dose holds or reductions will be recorded. |
Up to 18 months after completion or discontinuation of chemotherapy
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Olumide B. Gbolahan, MBBS, MSc、Emory University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- IRB00106610
- NCI-2018-02241 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- Winship4468-18 (その他の識別子:Emory University Hospital/Winship Cancer Institute)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。